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Tryptophan degradation in women with breast
cancer: a pilot study
Debra E Lyon1*, Jeanne M Walter1, Angela R Starkweather2, Christine M Schubert3 and Nancy L McCain2
Abstract
Background: Altered tryptophan metabolism and indoleamine 2,3-dioxygenase activity are linked to cancer
development and progression. In addition, these biological factors have been associated with the development
and severity of neuropsychiatric syndromes, including major depressive disorder. However, this biological
mechanism associated with both poor disease outcomes and adverse neuropsychiatric symptoms has received
little attention in women with breast cancer. Therefore, a pilot study was undertaken to compare levels of
tryptophan and other proteins involved in tryptophan degradation in women with breast cancer to women
without cancer, and secondarily, to examine levels in women with breast caner over the course of chemotherapy.
Findings: Blood samples were collected from women with a recent diagnosis of breast cancer (n = 33) before
their first cycle of chemotherapy and after their last cycle of chemotherapy. The comparison group (n = 24)
provided a blood sample prior to breast biopsy. Plasma concentrations of tryptophan, kynurenine, and tyrosine
were determined. The kynurenine to tryptophan ratio (KYN/TRP) was used to estimate indoleamine 2,3-dioxygenase
activity. On average, the women with breast cancer had lower levels of tryptophan, elevated levels of kynurenine
and tyrosine and an increased KYN/TRP ratio compared to women without breast cancer. There was a statistically
significant difference between the two groups in the KYN/TRP ratio (p = 0.036), which remained elevated in
women with breast cancer throughout the treatment trajectory.
Conclusions: The findings of this pilot study suggest that increased tryptophan degradation may occur in women
with early-stage breast cancer. Given the multifactorial consequences of increased tryptophan degradation in
cancer outcomes and neuropsychiatric symptom manifestation, this biological mechanism deserves broader
attention in women with breast cancer.
Background
Altered tryptophan metabolism and indoleamine 2,3-
dioxygenase (IDO) activity are linked to cancer develop-
ment and progression [1-4]. In addition, these biological
factors have been associated with the development and
severity of neuropsychiatric syndromes, including major
depressive disorder [5-8]. However, this biological
mechanism associated with both poor disease outcomes
and adverse neuropsychiatric symptoms has received lit-
tle attention in women with breast cancer (BCA)
although women with breast cancer have increased rates
of neuropsychiatric symptoms, not only during the
acute treatment phase but for some, into survivorship
[9-12]
Indoleamine (2,3)-dioxygenase (IDO) is an extrahepatic
enzyme that is overexpressed in many cancers and is acti-
vated in cancer cells as a strategy for immune escape, a
critical aspect of cancer progression [13]. IDO catalyzes
the initial and rate-limiting step of the catabolism of tryp-
tophan, an essential amino acid [14]. In cancer, tumors
generate an immunosuppressive microenvironment that
protects the tumor from host immunity, promotes tumor
growth, and attenuates immunotherapeutic efficacy [15].
Tryptophan depletion via IDO is part of the cytostatic
and antiproliferative activity mediated by interferon-g in
cells [16,17].
In addition to contributing to an environment that sup-
ports tumor development and progression, the biological
mechanisms associated with increased TRP degradation
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may contribute to neuropsychiatric symptoms in persons
with cancer through two metabolic pathways. First,
inflammatory activation or expression of IDO by tumor
cells can lead to elevated levels of IDO activity, which, in
turn, increases the degradation of TRP into kynurenine
(KYN) leaving less TRP available for other metabolic pro-
cesses [18]. As TRP is the primary amino acid precursor
of serotonin, systemic TRP depletion results in decreased
serotonin and melatonin synthesis [19]. In addition, the
production and build-up of kynurenic acid, a metabolite
of TRP degradation, inhibits the release of glutamate and
dopamine [20], important neurotransmitters for regulat-
ing neurocognitive function.
The concentration of TRP can also influence levels of
tyrosine (TYR), an important amino acid that is con-
verted to levodopa by the enzyme tyrosine hydroxylase
(TH) by dopaminergic cells in the brain [21]. In the
adrenal medulla, tyrosine is converted into catechola-
mine hormones, norepinephrine and epinephrine. In
addition, the thyroid hormones, triiodothyronine (T3)
and thyroxine (T4) in the colloid of the thyroid, are
derived from tyrosine and PN symptoms can develop
from excessive or deficient levels of T3 and T4 [22].
Therefore, a deficit in TRP availability may alter several
key hormones and neurotransmitters involved in main-
taining emotional and physical homeostasis.
Secondly, breakdown of TRP through the KYN path-
way leads to the production of a series of potentially
neurotoxic metabolites, such as quinolinic acid [20]. An
elevated level of quinolinic acid can lead to neurocogni-
tive dysfunction as well as other somatic and affective
symptoms. Elevated levels of IDO with a subsequent
acceleration of TRP degradation along with changes in
the availability of key hormones, neurotransmitters, and
the accumulation of neurotoxic metabolites could repre-
sent an important cascade of events that occur between
the proinflammatory state produced by cancer or its
treatment and the manifestation of PN symptoms
[23-25].
Studies in cancer provide some support for the role of
increased TRP degradation in systemic immune activa-
tion, severity of physical symptoms, regulation of
immune cells within the tumor microenvironment, and
in the progression of disease. An increased KYN/TRP
ratio and reduced level of TRP correlated with immune
activation and reduced quality of life in patients with
colorectal liver metastases [26]. In this study, serum
TRP was an independent predictor of physical symptom
scores measured by the Rotterdam Symptom Checklist
and Sickness Impact Profile. In patients with colorectal
cancer, the level of IDO expression within tumors corre-
lates inversely with the number of tumor infiltrating
cells and the clinical outcome of colorectal cancer
patients [27]. Tumor cells with high expression of IDO
avoid immune attack by local TRP depletion and the
production of proapoptotic TRP catabolites. IDO activity
(KYN/TRP ratio) was significantly higher in 123 patients
with lung cancer compared to a control (no cancer)
group (47.1 ± 21.3 vs. 32.9 ± 9.10, respectively; p < 0.01)
[28]. In addition, patients with advanced lung cancer
had significantly higher IDO activity and lower TRP
concentrations than those in the early stages (p = 0.005
and p = 0.021 respectively) suggesting that TRP degra-
dation may occur more significantly with advanced stage
cancer [28]. Increased synthesis of IDO protein was
positively associated with impaired survival in women
with ovarian serous adenocarcinomas [29]. While these
studies suggest critical relationships among TRP meta-
bolism, immune regulation and disease progression in
cancer, there has been little study TRP degradation in
patients with BCA. Therefore, given the importance of
further understanding the biological mechanisms asso-
ciated with BCA and neuropsychiatric symptoms, a pilot
study was undertaken to compare levels of TRP and
other proteins involved in TRP degradation in women
with BCA to women without cancer, and secondarily, to
examine levels in women with BCA over the course of
chemotherapy.
Methods
Study Design
This was a prospective pilot study to compare levels of
TRP and other proteins involved in TRP degradation in
women with BCA and women without cancer, and sec-
ondarily, to examine how levels change over the course
of chemotherapy. Based on past research [9-12], women
with BCA typically experience worsening symptoms as
treatment progresses, with the most severe neuropsy-
chiatric symptoms occurring after the completion of
chemotherapy. Therefore, data collection time points
were selected for participants with BCA before the
initial dose of chemotherapy was administered and after
the cessation of chemotherapy.
Sample and Setting
For this study, two groups of women were recruited;
women recently diagnosed with BCA and a comparison
group of women without BCA (confirmed by a negative
breast biopsy). Women older than 21 years of age with
a first-time diagnosis of Stage I-III BCA and women
undergoing breast biopsy for a suspicious breast lesion
were invited to participate. Exclusion criteria included
previous diagnosis of BCA or any other type of cancer,
current use of antidepressants or other medications that
interfere with TRP metabolism, and English proficiency.
Participants were recruited from two university health
systems in the mid-Atlantic region of the United States.
Women with BCA (N = 33) were approached about
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study participation after their 4th week post-surgery
(lumpectomy or mastectomy) but before receiving their
first dose of chemotherapy. Participants in the compari-
son group (N = 24) were approached prior to breast
biopsy for a suspicious breast lesion and all participants
in this group had a negative biopsy result. Due to the
exploratory nature of this study, the sample size estima-
tion was based on having 12 participants for each of the
main variables, TRP and IDO. Recruitment continued
until there were at least 24 participants in each group.
Each participant verbalized understanding and gave
informed consent to the respective protocols, which
were approved by the university’s institutional review
board.
Procedures
Blood samples were obtained using a standard phlebot-
omy protocol at the time of consent. Blood was collected
in a serum separator vacutainer without anticoagulant
and allowed to coagulate for 20 to 30 minutes at room
temperature. Sera were separated by centrifugation, and
all specimens were aliquoted immediately, frozen and
stored at -70°C until batch processing [30].
The concentrations of TRP, KYN, and TYR were mea-
sured simultaneously by high performance liquid chroma-
tography (HPLC) equipment with fluorescence detection
according to Costa et al. [21]. The laboratory of
Dr. George Anderson at Yale University performed the
assays using previously validated modifications of pub-
lished methods [31,32]. Samples were prepared by depro-
teinization after addition of internal standard (a-
methyltryptophan). Supernates were directly injected onto
a reverse phase HPLC system, and measurements were
detected fluorometrically (285 and 345 nm excitation and
emission wavelengths, respectively). A quality assessment
("QC”) sample was included in all runs and compounds
were detected with within-day and day-to-day coefficients
of variation (CVs) of less than 5% and 7%, respectively.
Using the formula described by Myint et al. [19], IDO
activity was estimated as the ratio of KYN to TRP.
Data analysis
Data analysis was conducted using SAS version 9.1.3
(SAS Institute, North Carolina), and the significance
level was set at a < .05. Participants with missing data
were not included in the analysis. Means and confidence
intervals were used to examine the distribution of the
data. Failing equality of variance tests, differences
between groups, women with BCA and women without
cancer (comparison group), were tested with indepen-
dent t-tests assuming unequal variances and with inde-
pendent t-tests assuming equal variances for TRP, KYN,
and TYR. Bonferroni corrections for multiple t-tests
were employed as necessary.
Results
The women with BCA and those in the comparison
group were similarly aged (means 50.0 ± 11.0 and 47.8
± 7.6 years respectively, p = 0.76). Descriptive statistics
for women with BCA prior to and after chemotherapy
(baseline and time 2) and women in the comparison
group are listed in Table 1.
On average, the women with BCA had higher levels of
KYN, TYR, and IDO activity (KYN/TRP ratio) and lower
levels of TRP than women in the comparison group.
Means and 95% confidence intervals for these proteins
are plotted in Figure 1. The KYN pathway is constitu-
tively active in the liver, and a basal concentration of
KYN is typically found in serum at approximately 1.92 ±
0.58 μmol/L in healthy individuals, whereas concentra-
tions of free TRP range from 40 to 100 μmol/L [31].
Variabilities in KYN and KYN/TRP ratios were much
higher in the women with BCA than in women without
BCA (comparison group) and noticeably higher levels of
TYR were found for women with BCA (Figure 1).
Women with BCA had a significantly higher KYN/TRP
ratio (p = 0.036) than the women in the comparison
group. There were no statistically significant differences
between these women with regard to KYN (p = -0.18),
TRP (p = 0.16), or TYR (p = 0.54). Means by measure-
ment time-point for the women with BCA are plotted in
Figure 2 and listed in Table 2. Although there were
decreases in KYN, TRP, KYN/TRP ratio and increases
in TYR in women with BCA from baseline to T2, these
changes were not statistically significant.
Discussion
This pilot study was conducted to compare plasma con-
centrations of TRP, KYN, and TYR between women
with BCA and women without cancer, and to determine
how levels change over the course of BCA treatment.
The sample of women with BCA in this study had lower
levels of TRP and higher levels of KYN and TYR com-
pared to women without BCA (comparison group).
Although these differences did not reach statistical sig-
nificance, the findings suggest that there may be quanti-
tative differences in the levels of KYN and TYR.
Because KYN and TYR are potentially neurotoxic, this
finding needs to be further examined. Women with
BCA also had a significantly higher KYN/TRP ratio
compared to women without cancer. Findings of an ele-
vated KYN/TRP ratio in this pilot study are consistent
with one previous research study that found significantly
higher IDO levels in serum and higher expression of
IDO from breast tissue samples in 30 women with BCA
compared to a control (no cancer) group [33]. In that
study, the serum levels and expression of IDO did not
correlate with histologic classification, tumor size, lym-
phatic or venous invasion, or lymph node metastasis but
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was significantly correlated with the serum level of
immunosuppressive acidic protein (IAP), a biomarker of
systemic immunodepression, suggesting that increased
levels of IDO were induced by changes in immune func-
tion as opposed to breast tumor IDO secretion. Levels
of TRP, KYN, and TYR were not reported, thus, no
inferences were made about the effect of IDO on TRP
degradation. However, the present study findings sug-
gest that increased TRP degradation is present in
women with BCA due to increased KYN along with
decreased TRP.
The results of the current study support the need for
further research of increased TRP degradation as a poten-
tial biological mechanism in breast cancer outcomes and
symptom research. A deeper understanding of the rela-
tionships among neuropsychiatric symptoms and TRP
degradation over the treatment trajectory may assist in the
development of new symptom management approaches.
For instance, IDO activity (measured indirectly by the
KYN/TRP ratio) and an increased neurotoxic potential
predict the occurrence of depression in patients with
hepatitis C being treated with IFN-a based immunother-
apy [34,35]. The neurotoxic potential (KYN/kynurenic
acid ratio) is an indicator of the portion of KYN available
to the N-methyl-D-aspartate (NMDA) receptor antagonist
pathway and more precisely gauges the TRP and KYN
levels within the central nervous system [36,37].
Consistent with previous research, the women with
BCA had lower levels KYN and KYN/TRP ratio after
the completion of chemotherapy [33], however the level
of TRP continued to decline. While we cannot make
any inferences about the effectiveness of chemotherapy
in this study, past research findings suggest that the
KYN/TRP ratio may be a useful indicator of treatment
efficacy. Sakurai et al. [38] measured the KYN/TRP ratio
in women with recurrent BCA who were receiving che-
motherapy and compared levels between two different
regimens, paclitaxel and docetaxel therapy. They found
that women treated with docetaxel had higher KYN/
TRP ratios post-chemotherapy compared to women
receiving paclitaxel, suggesting the paxitaxel regimen
may be more effective in eradicating IDO-secreting
tumor cells. The KYN/TRP ratio also been used to pre-
dict prognosis and recurrence in patients with colorec-
tal, lung, and ovarian cancer [26-29]. Given the
multifactorial role of IDO and TRP, further research is
necessary to determine the relationships among these
important biological factors and neuropsychiatric symp-
toms, treatment efficacy, prognosis, and recurrence in
women with BCA.
Study limitations
There are several limitations of the present findings
which should be discussed, most notably the small sam-
ple size in each group. Although the research team cal-
culated the sample size estimate based on past research,
a more robust sample size may have improved the
power to detect significant differences in levels of TRP,
Table 1 Descriptive Statistics for Women in the Comparison Group and Women with Breast Cancer at Baseline (Time 1)
and After Completion of Chemotherapy (Time 2)
n mean median std stderr 95% LCL 95% UCL
Comparison Group (Benign Breast Biopsy)
Kynurenine (μmol/l) 24 1.98 1.92 0.43 0.09 1.79 2.16
Tryptophan (μmol/l) 24 52.89 51.90 10.44 2.13 48.48 57.30
Kyn/Trp ratio (μmol/l μmol) 24 3.81 3.81 0.88 0.18 3.44 4.18
Tyrosine (μmol/l) 24 81.70 76.63 26.20 5.35 70.64 92.77
Age (years) 24 49.96 48.50 10.98 2.24 45.32 54.60
Breast Cancer Group
Time 1 (Baseline - Prior to Induction of Chemotherapy)
Kynurenine (μmol/l) 33 2.27 2.05 1.13 0.20 1.87 2.67
Tryptophan (μmol/l) 33 48.86 47.62 10.68 1.86 45.08 52.65
Kyn/Trp ratio (μmol/l μmol) 33 4.62 4.10 1.88 0.33 3.95 5.28
Tyrosine (μmol/l) 32 85.43 81.49 19.12 3.38 78.53 92.32
Age (years) 33 47.76 50.00 7.58 1.32 45.07 50.45
Time 2 (After Completion of Chemotherapy)
Kynurenine (μmol/l) 30 2.00 1.97 0.66 0.12 1.75 2.24
Tryptophan (μmol/l) 30 48.14 49.82 10.81 1.97 44.11 52.18
Kyn/Trp ratio (μmol/l μmol) 30 4.23 3.99 1.36 0.25 3.72 4.74
Tyrosine (μmol/l) 30 86.44 83.99 20.76 3.79 78.69 94.19
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KYN and TYR. In addition, findings of the study could
also be critiqued in relation to the sample of women
with BCA, which was primarily composed of women
with early stage BCA and did not permit subgroup ana-
lysis by BCA stage. Systemic inflammatory processes
play a key role in the initiation and progression of
cancers and have been shown to potently induce IDO
activity [39]. Finally, other biological factors that were
not measured in this study, particularly, inflammatory
molecules, can alter the activity of IDO both indirectly
through the siphoning of TRP along the KYN pathway
and by direct enhancement of their metabolism [14].
Conversely, drugs that inhibit IDO or TDO can poten-
tially modify the levels of all these compounds, both
directly and through changes in the availability of TRP
[40]. Future research studies should consider measuring
inflammatory markers and controlling for the type of
chemotherapeutic regimen as a strategy to clarify how
these factors influence TRP degradation and the devel-
opment of neuropsychiatric symptoms in women with
BCA.
Conclusion
The sample of women with BCA in this study had lower
mean levels of TRP, higher levels of KYN, and a
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significantly elevated KYN/TRP ratio, compared to
women without BCA. In women with BCA, the KYN/
TRP ratio remained elevated with reduced levels of TRP
over the treatment trajectory. These findings are consis-
tent with increased TRP degradation and support the
need for further lines of inquiry about the relationships
among TRP and TRP metabolites, other biological factors
along the IDO-KYN pathway, and neuropsychiatric
symptoms in women with BCA. Interrelationships among
several key biological processes are likely to influence
co-occuring symptoms associated with BCA and its treat-
ment, including immune activation, stimulation of IDO
activity, and subsequent TRP degradation. Systemic mani-
festations of TRP degradation may depend on the stage
of BCA as well as the temporal nature of the disease pro-
cess and degree of systemic inflammation.
Acknowledgements and Funding
Components of the research were supported by the National Cancer
Institute through grant #R21 CA (D. Lyon, PI) and the National Institute for
Nursing Research through grant #P20 NR008988 (N. McCain, PI).
Author details
1Department of Family and Community Health Nursing, Virginia
Commonwealth University School of Nursing, 1100 East Leigh Street,
Richmond, Virginia, 23298, USA. 2Department of Adult Health and Nursing
Systems, Virginia Commonwealth University School of Nursing, 1100 East
Leigh Street, Richmond, Virginia, 23298, USA. 3Department of Mathematics
and Statistics, Air Force Institute of Technology, 2950 Hobson Way, Wright-
Patterson Air Force Base, Ohio, 45433, USA.
Authors’ contributions
DEL conceived of the study and participated in its design and coordination,
and helped to draft the manuscript. JMW participated in data collection,
analysis and helped to draft the manuscript. ARS participated in data analysis
and helped to draft the manuscript. CMS participated in the design of the
study and performed the statistical analysis. NLM participated in the design
of the study, data analysis and helped to draft the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 January 2011 Accepted: 26 May 2011
Published: 26 May 2011
References
1. Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP,
Traversari C, Bellone M, Corti A: Critical role of indoleamine 2,3-
dioxygenase in tumor resistance to repeated treatments with targeted
IFNgamma. Mol Cancer Ther 2008, 7:3859-3866.
2. Girgin G, Sahin TT, Fuchs D, Kasuya H, Yuksel O, Tekin E, Baydar T: Immune
system modulation in patients with malignant and benign breast
disorders: Tryptophan degradation and serum neopterin. Int J Biol
Markers 2009, 24:265-270.
3. Stone TW, Darkington LG: Endogenous kynurenines as targets for drug
discovery and development. Nat Rev Drug Discov 2002, 1:609-620.
4. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N,
Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance
mechanism based on tryptophan degradation by indoleamine 2,3-
dioxygenase. Nat Med 2003, 9:1269-1274.
5. Almeida-Montes LG, Valles-Sanchez V, Moreno-Aguilar J, Chavez-Balderas RA,
Garcia-Marin JA, Cortes Sotres JF, Hheinze-Martin G: Relation of serum
cholesterol, lipid, serotonin and tryptophan levels to severity of
depression and to suicide attempts. J Psychol Neurobiol 2000, 25:371-377.
6. Maes M, Ombelet W, Verkerk R, Bosmans E, Sharpe S: Effects of pregnancy
and delivery on the availability of plasma tryptophan to the brain:
Relationships to delivery-induced immune activation and early post-
partum anxiety and depression. Psychiatr Med 2001, 31:847-858.
7. Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D’Hondt P,
Bossche BV, Cosyns P: Increased neopterin and interferon-gamma
secretion and lower availability of L-tryptophan in major depression:
further evidence for an immune response. Psychol Res 1994, 54:143-160.
8. Maes M, Verkerk R, Vandoolaeghe E, Van Hunsel F, Neels H, Wauters A,
Demedts P, Scharpe S: Serotonin-immune interactions in major
depression: Lower serum tryptophan as a marker of an immune-
inflammatory response. Eur Arch Psych Clin Neurosci 1997, 247:154-161.
9. Bender CM, Ergyn FS, Rosenzweig MQ, Cohen SM, Sereika SM: Symptom
clusters in breast cancer across 3 phases of the disease. Cancer Nurs
2005, 28:219-225.
10. Glaus A, Boehme C, Thurlimann B, Ruhstaller T, Hsu Schmitz SF, Morant R,
Senn HJ, von Moos R: Fatigue and menopausal symptoms in women
with breast cancer undergoing hormonal cancer treatment. Ann Oncol
2006, 17:801-806.
11. Quesnel C, Savard J, Ivers H: Cognitive impairments associated with
breast cancer treatments: results from a longitudinal study. Breast Can
Res Treat 2009, 116:113-123.
12. Vardy J, Tannock I: Cognitive function after chemotherapy in adults with
solid tumours. Crit Rev Oncol Hematol 2007, 63:183-202.
13. Muller AJ, DuHadaway JB, Scott Donover P, Sutanto-Ward E,
Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an
immunoregulatory target of the cancer suppression gene Bin1,
potentiates cancer chemotherapy. Nat Med 2005, 11:312-319.
14. Clarke G, Fitzgerald P, Cryan JF, Cassidy EM, Quigley EM, Dinan TG:
Tryptophan degradation in irritable bowel syndrome: Evidence of
indoleamine 2,3-dioxygenase activation in a male cohort. BMC
Gastroenterology 2009, 9:6.
15. Zou W: Immunosuppressive networks in the tumor environment and
their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
16. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D: Monitoring tryptophan
metabolism in chronic immune activation. Clin Chim Acta 2006, 364:82-90.
17. Konan KV, Taylor MW: Importance of the two interferon-stimulated
response element (ISRE) sequences in the regulation of the human
indoleamine 2,3-dioxygenase gene. J Biol Chem 1996, 271:19140-19145.
18. Barry S, Clark G, Scully P, Dinan TG: Kynurenine pathway in psychosis: Evidence
of increased tryptophan degradation. J Psychopharmacol 2009, 23:287-294.
19. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HWM,
Leonard BE: Tryptophan breakdown pathway in bipolar mania. J Affect
Disord 2007, 102:65-72.
Table 2 Mean Changes in Biological Factors in Women with Breast Cancer from Baseline (Time 1) to After Completion
of Chemotherapy (Time 2)
mean median std stderr min max 95% LCL1 95% UCL2 p-values
Kynurenine -0.28 0.08 1.12 0.21 -4.11 0.82 -0.70 0.13 0.91
Tryptophan -0.30 -2.56 11.16 2.04 -17.12 25.68 -4.47 3.87 0.88
Kyn/Trp ratio -0.45 0.25 2.00 0.37 -5.76 2.04 -1.20 0.30 0.92
Tyrosine 0.38 3.08 21.48 3.92 -31.55 53.50 -7.64 8.40 0.92
1 Upper control limit
2 Lower control limit
Lyon et al. BMC Research Notes 2011, 4:156
http://www.biomedcentral.com/1756-0500/4/156
Page 6 of 7
20. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M: IDO and
interferon-alpha-induced depressive symptoms: A shift in hypothesis
from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005,
10:538-544.
21. Costa E, Spano PG, Groppetti A, Algeri S, Neff NH: Simultaneous
determination of tryptophan, tyrosine, catecholamines and serotonin
specific activity in rat brain. Atti Accad Med Lomb 1968, 23:1100-1104.
22. Maes M, Capuron L, Ravaud A, Gualde N, Bosmans E, Egyed B, Dantzer R,
Neveu PJ: Lowered serum dipeptidylpeptidase IV activity is associated
with depressive symptoms and cytokine production in cancer patients
receiving interleukin-2-based immunotherapy. Neuropsychopharm 2001,
24:130-140.
23. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR: Neuroendocrine-
immune mechanisms of behavioral comorbidities in patients with
cancer. J Clin Oncol 2008, 26:971-982.
24. Kurz K, Schroecksnadel S, Weiss G, Fuchs D: Association between
increased tryptophan degradation and depression in cancer patients.
Curr Opin Clin Nutr Metab Care 2011, 14:49-56.
25. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R: Association
between decreased serum tryptophan concentrations and depressive
symptoms in cancer patients undergoing cytokine therapy. Mol
Psychiatry 2002, 7:468-473.
26. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG:
Serum tryptophan decrease correlates with immune activation and
impaired quality of life in colorectal cancer. Br J Cancer 2002,
86:1691-1696.
27. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P,
Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Vabel GG, Margreiter R,
Vanigsrainer AK, Fuchs D, Amberger A: Prognostic value of indoleamine
2,3-dioxygenase expression in colorectal cancer: Effect on tumor
infiltrating cells. Clin Cancer Res 2006, 12:1144-1151.
28. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y,
Inui N, Nakamura H, Chida K: Increased serum kynurenine/tryptophan
ratio correlates with disease progression in lung cancer. Lung Cancer
2009, 67:361-365.
29. Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M,
Okamoto S, Takikawa O, Sasaki H, Yusada M, Ochiai K, Tanaka T: Increased
synthesis of indoleamine 2,3-dioxygenase protein is positively associated
with impaired survival in patients with serous-type, but not with other
types of, ovarian cancer. Oncol Rep 2007, 17:1333-1339.
30. Lyon DE, McCain NL, Walter J, Schubert C: Cytokine comparisons between
women with breast cancer and women with a negative breast biopsy.
Nurs Res 2008, 57:51-58.
31. Anderson GM, Freedman DX, Cohen DJ, Volkmar FR, Hoder EL,
McPhedran P, Minderaa RB, Hansen CR, Young JG: Whole blood serotonin
in autistic and normal subjects. J Child Psychol Psychiatry 1987, 28:885-900.
32. Kirwin PD, Anderson GM, Chappell PB, Saberski L, Leckman JF, Geracioti TD,
Heninger GR, Price LH, McDougle CJ: Assessment of diurnal variation of
cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid
concentrations in healthy human females. Life Sci 1997, 60:899-907.
33. Sakurai K, Amano S, Enomoto K, Kashio M, Saito Y, Sakamoto A, Matsuo S,
Suzuki M, Kitajima A, Hirano T, Negishi N: Study of indoleamine 2, 3-
dioxygenase expression in patients with breast cancer. Gan To Kagaku
Ryoho 2005, 32:1546-1549.
doi:10.1186/1756-0500-4-156
Cite this article as: Lyon et al.: Tryptophan degradation in women with
breast cancer: a pilot study. BMC Research Notes 2011 4:156.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lyon et al. BMC Research Notes 2011, 4:156
http://www.biomedcentral.com/1756-0500/4/156
Page 7 of 7
